On the other hand, the currently available advanced AID systems (able to predict impending episodes of hypoglycemia or hyperglycemia and to promptly and dynamically adjust insulin delivery), together with future CKM systems, may help effectively prevent the most dreaded adverse effects of incretin analogs in T1D patients, namely hypoglycemia, DKA and euDKA. The gene discussed is INS; the disease is type 1 diabetes mellitus.